Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Cash & Equivalents (2016 - 2025)

Outlook Therapeutics (OTLK) has disclosed Cash & Equivalents for 8 consecutive years, with $8.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash & Equivalents rose 52.17% to $8.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $8.7 million, a 52.17% increase, with the full-year FY2025 number at $8.1 million, changed N/A from a year prior.
  • Cash & Equivalents was $8.7 million for Q4 2025 at Outlook Therapeutics, up from $8.1 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $8.9 million in Q2 2025 to a low of $5.7 million in Q4 2024.